BidaskClub downgraded shares of Athenex (NASDAQ:ATNX) from a hold rating to a sell rating in a report released on Thursday morning.
ATNX has been the subject of a number of other reports. JPMorgan Chase & Co. began coverage on shares of Athenex in a report on Wednesday, October 18th. They set a neutral rating and a $22.20 price objective for the company. Laidlaw began coverage on shares of Athenex in a report on Tuesday, September 19th. They set a buy rating and a $36.00 price objective for the company. Credit Suisse Group initiated coverage on shares of Athenex in a report on Monday, September 18th. They set an outperform rating and a $25.00 price objective for the company. Finally, Royal Bank of Canada initiated coverage on shares of Athenex in a report on Thursday, September 14th. They set an outperform rating and a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $27.64.
Shares of Athenex (ATNX) traded down $0.33 during midday trading on Thursday, hitting $15.61. 73,000 shares of the stock were exchanged, compared to its average volume of 150,967. The firm has a market capitalization of $904.73 and a PE ratio of -5.66. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.